Benyam Muluneh
Overview
Explore the profile of Benyam Muluneh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
218
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Muluneh B, Collins J, Lam B, Mackler E, Lafata J
J Natl Compr Canc Netw
. 2024 Mar;
22(3):167-174.
PMID: 38503050
Background: Oral anticancer agents (OAAs) transformed cancer care for patients, extending survival and delaying progression in certain cases. There are multiple pharmacy-driven models to improve patient knowledge and adherence to...
12.
Lam B, Rodgers J, Muluneh B, Proco D, Whang Y, Morgan K
Ann Pharmacother
. 2024 Feb;
58(10):994-1002.
PMID: 38344981
Background: Abiraterone acetate (AA) is used in treatment of patients with metastatic prostate cancer. Despite the survival advantage, AA is associated with hypertension due to mineralocorticoid excess syndrome. Objective: We...
13.
Collins J, Muluneh B, Profitt S
J Oncol Pharm Pract
. 2023 Dec;
30(2):385-396.
PMID: 38105466
Tyrosine kinase inhibitors (TKIs) are the mainstay of treatment for chronic myeloid leukemia (CML). Patients enrolled in clinical trials investigating the safety and efficacy of TKIs in CML are generally...
14.
Signorelli J, Tran T, Sirek M, Diaz-Rohena Y, Taraba J, Muluneh B, et al.
J Oncol Pharm Pract
. 2023 Oct;
30(8):1307-1316.
PMID: 37899586
Introduction: To date, there is no adherence estimator to identify risk of nonadherence prior to initiating oral oncolytics. Methods: A workgroup was assembled through the National Community Oncology Dispensing Association...
15.
Muluneh B, Muir M, Collins J, Proco D, Mackler E, Bryant A, et al.
PLoS One
. 2023 Jul;
18(7):e0286630.
PMID: 37478078
Purpose: The goal of this study is to determine barriers and facilitators to the implementation of medication adherence interventions to support cancer patients taking novel, targeted oral anticancer agents (OAAs)....
16.
Eisinger C, Muluneh B
J Oncol Pharm Pract
. 2023 May;
29(6):1461-1466.
PMID: 37231712
Objective: The purpose of this article is to review the pharmacology, safety, evidence for current use, and potential futures uses for combination therapy with pembrolizumab and lenvatinib. Data Sources: A...
17.
Zunich R, Roberts M, Blanchard C, Muluneh B, Carlson R, Helms T
JCO Oncol Pract
. 2022 Dec;
19(1):e43-e52.
PMID: 36475754
Purpose: Team-based care is the delivery of health services to an individual by at least two health care providers working collaboratively to achieve optimal care. Participants on the National Cancer...
18.
Palmer S, Patel A, Wang C, Patel B, Zeidner J, Foster M, et al.
J Oncol Pharm Pract
. 2022 Dec;
29(7):1590-1598.
PMID: 36474407
Introduction: Venetoclax is a treatment option in patients with acute myeloid leukemia (AML) in both the front-line and relapsed/refractory settings. Initiation of therapy has been previously restricted to the inpatient...
19.
Fentie A, Mekonen Z, Gizachew Z, Hailemariam M, Clark S, Richardson J, et al.
Pediatr Hematol Oncol
. 2022 Oct;
40(3):258-266.
PMID: 36308760
Optimal chemotherapy management is substandard in low and middle-income countries. We aimed to identify major gaps to design interventional strategies for improved chemotherapy management at Tikur Anbessa Specialized Hospital (TASH),...
20.
Stocker K, Tiemann A, Brunk K, Agegnehu B, Buhlinger K, Amerine L, et al.
J Oncol Pharm Pract
. 2022 Oct;
29(7):1555-1564.
PMID: 36303425
Background: The impact and downstream effects of the chemotherapy supply chain in Ethiopia are not well understood. The purpose of this study was to identify perceived gaps in supply chain...